USPTO Patent Application: IL-17 Antibody Compositions

The USPTO has published a patent application (US20260083842A1) detailing pharmaceutical products and stable liquid compositions of IL-17 antibodies, such as secukinumab. The application covers methods of making these compositions and their use in treating IL-17-mediated disorders, including autoimmune conditions like psoriasis and rheumatoid arthritis.

Bispecific Molecule Stabilizing Composition Patent Application

The USPTO has published a patent application (US20260083841A1) for a pharmaceutical composition designed to stabilize bispecific antigen-binding molecules at increased concentrations. The composition includes buffer agents, saccharides, and specific stabilizing agents like EDTA or citric acid.

USPTO Patent Application: NEO-201 Antibody for Suppressing Myeloid Derived Suppressor Cells

The USPTO has published a patent application (US20260083840A1) detailing methods for ablating myeloid derived suppressor cells using the NEO-201 antibody. The application describes the antibody's specific binding to certain O-glycans and its potential use in treating cancers and infectious diseases by suppressing gMDSCs.

USPTO Patent Application: Treating NSCLC with Dostarlimab or Biosimilar

The USPTO has published a patent application detailing a method for treating non-small cell lung cancer (NSCLC) using dostarlimab or a biosimilar. The application outlines a treatment approach for patients previously treated with an immune checkpoint inhibitor.

USPTO Patent Application: Modified Coronavirus Spike Antigen Protein

The USPTO has published a patent application (US20260083836A1) for a modified coronavirus spike antigen protein. The application describes a protein designed to suppress cell membrane fusion ability and improve safety by modifying cleavage sites, aiming to enhance vaccine efficacy and antibody production.

USPTO Patent Application: Phage T4 Nanoparticle Vaccine Platform

The USPTO has published a patent application (US20260083835A1) detailing a modular bacteriophage T4 nanoparticle vaccine platform. This platform is designed for the rapid development of dual COVID-19 and flu mucosal vaccines, administered intranasally without an adjuvant.

USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery

The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.

USPTO Patent Application: Engineered Probiotics Expressing Anti-Inflammatory Molecules

The USPTO has published a patent application (US20260083783A1) from the University of Cincinnati for engineered probiotics that express anti-inflammatory molecules. The application details a genetically modified E. coli bacterium designed to produce a microbial anti-inflammatory molecule (MAM) protein.

USPTO Patent Application for Generating CD4 T Cells

The USPTO has published a patent application (US20260083778A1) for methods of generating CD4 T cells from progenitor cells. The application, assigned to Boston Medical Center Corporation, describes a specific differentiation process for therapeutic use.

USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment

The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.